https://www.selleckchem.com/products/xst-14.html
5 and 2.1 times on the 3 and 5 days, respectively. In the MB group compared with the SOC group, the rate ratio of RR improvement was 10.1 and 3.7 times on the 3 and 5 days, respectively. The hospital stay was significantly shortened in the MB group (p = 0.004), and the mortality was 12.5% and 22.5% in the MB and SOC groups, respectively. The addition of MB to the treatment protocols significantly improved SpO and respiratory distress in COVID-19 patients, which resulted in decreased hospital stay and mortality. ClinicalTrials.gov NCT0437